ABSTRACT
Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams (PERTs) show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of healthcare, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must be routinely monitored to fully capture the impact of modern PE treatment. We set out to standardize data collection in PE patients undergoing evaluation and treatment, and thus establish the foundation for an expanding evidence base that will address gaps in evidence and inform future care for acute PE. To do so, over 100 international PE thought leaders convened in Washington, DC in April 2022 to form the Pulmonary Embolism Research Collaborative (PERC™). Participants included physician experts, key members of the United States Food and Drug Administration (FDA), patient representatives, and industry leaders. Recognizing the multi-disciplinary nature of PE care, the Pulmonary Embolism Research Collaborative (PERC™) was created with representative experts from stakeholder medical subspecialties, including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through PERC™, as it is applied to data collection, promises to provide crucial knowledge that will ultimately produce a robust evidence base that will lead to standardization and harmonization of PE management and improved outcomes.
What is new?
Recent advances have increased options for treatment of acute pulmonary embolism, yet there remain wide variations in management due to the lack of a reliable evidence base upon which to base therapeutic decisions.
The PERT ConsortiumTM is a strong advocate of evidence based care for PE patients and therefore initiated the Pulmonary Embolism Research Collaborative (PERCTM) to establish a foundation for advancing high quality research and improving clinical care.
A novel comprehensive set of standardized data elements is proposed for collection in patients with acute pulmonary embolism, to provide a foundation for expanding the evidence base and enhancing care.
What are the clinical implications?
Standardizing collection of data for acute pulmonary embolism will enable analyses that will inform optimal risk stratification, treatment, and follow-up of patients with pulmonary embolism, and provide evidence-based treatment algorithms that will improve outcomes.
Registries created using the proposed standardized elements will enable benchmarking and quality assurance for clinicians caring for pulmonary embolism patients.
Incorporation of comprehensive standardized data elements into FDA IDE trials will enable the Agency to better assess the safety and effectiveness of investigational devices.
Competing Interest Statement
To be submitted on line by individuals. These were previously provided with prior submission and are unchanged.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A for this Manuscript
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
On behalf of attendees at the inaugural PERCTM meeting held in Washington DC on April 22, 2022 (See Appendix 2 for full listing)
Data Availability
All data are original
ABBREVIATIONS
- AI
- Artificial Intelligence
- AC
- Anticoagulation; Anticoagulant
- CBT
- Catheter-based Thrombectomy
- CDL
- Catheter-directed Thrombolysis
- CDER
- Center for Drug Evaluation and Research
- CDRH
- Center for Devices and Radiological Health
- CPET
- Cardiopulmonary Exercise Testing
- CTEPD
- Chronic Thromboembolic Pulmonary Disease (also referred to as CTED)
- CTEPH
- Chronic Thromboembolic Pulmonary Hypertension
- ECMO
- Extracorporeal Membrane Oxygenation
- EMR
- Electronic Medical Record
- ESC
- European Society of Cardiology
- FDA
- Food and Drug Administration
- MCS
- Mechanical Circulatory Support
- PE
- Pulmonary Embolism
- PERC
- Pulmonary Embolism Research Collaborative
- PERT
- Pulmonary Embolism Response Team
- PRO
- Patient Reported Outcome
- VTE
- Venous Thromboembolism
